Navigation Links
Boston Scientific Welcomes Introduction of Medical Device Regulatory Improvement Act in U.S. Senate
Date:10/14/2011

NATICK, Mass., Oct. 14, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) welcomes yesterday's introduction of the Medical Device Regulatory Improvement Act, sponsored by Sen. Amy Klobuchar (D-MN) and cosponsored by Sens. Richard Burr (R-NC) and Michael Bennet (D-CO).  The legislation is intended to streamline the medical device review and approval process, reduce regulatory delays and help new medical technologies safely and more expeditiously reach patients.

Boston Scientific commends Senators Klobuchar, Burr and Bennet for their thoughtful leadership in introducing this new legislation designed to streamline the Food and Drug Administration's regulation of medical devices.  This bill is an important step in transforming the process of bringing life-enhancing and life-saving medical technologies to market in a safe and more efficient and predictable manner. 

Boston Scientific looks forward to collaborating with the sponsoring senators and other Members of Congress on this important piece of legislation.

About Boston ScientificBoston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com.   CONTACT:

Erik Kopp508-650-8660 (office)Media RelationsBoston Scientific Corporationerik.kopp@bsci.comSean Wirtjes508-652-5305 (office)Investor RelationsBoston Scientific Corporationinvestor_relations@bsci.com
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Boston Scientific To Webcast Conference Call Discussing Third Quarter 2011 Financial Results
2. COPAN WASP® Lands at Prestigious Boston Medical Center
3. Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial
4. Boston Scientific Announces Favorable Appellate Court Ruling Affirming Non-Infringement of Johnson & Johnson Patent
5. Bluestar Silicones to Present Antimicrobial Silicones at Medical Silicones Conference in Boston
6. Clinical Data Demonstrates Long-Term Safety of Boston Scientifics Alair[TM]Bronchial Thermoplasty System
7. Boston Scientific Launches Coyote™ Balloon Catheter
8. Boston Scientific Sponsors New Patient Portal Dedicated to Pelvic Floor Disorders
9. Boston Scientific Names Michael F. Mahoney as Company President, Announces CEO Transition Plan
10. ConvaTec Announces Acquisition of Boston Medical Device
11. Cumberland Pharmaceuticals to Present at the Stifel Nicolaus 2011 Healthcare Conference in Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... and LONDON , Nov. 25, ... AstraZeneca (NYSE: AZN ) today announced that AMAGINE-2 ... doses of brodalumab in more than 1,800 patients with moderate-to-severe ... Stelara ® (ustekinumab) and placebo at week 12. Brodalumab ... analysis group were each shown to be superior to Stelara ...
(Date:11/26/2014)... China , Nov. 26, 2014 / -- China Nepstar Chain ... "Company"), a leading retail drugstore chain in ... operated stores, today announced the appointment of Ms. ... Officer, effective immediately. Ms.Zhang has over ... joined Nepstar in March 1999. Prior to Ms. Zhang,s ...
(Date:11/24/2014)... -- Juno Therapeutics today announced that the FDA ... JCAR015 chimeric antigen receptor product candidate.  The designation ... B-cell acute lymphoblastic leukemia and was filed by ... where Phase 1 clinical trials are currently underway. ... news for patients who may benefit from the ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 2China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 3Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3
... multiple sclerosis, remained relapse-free after three years of treatment ... active brain lesions - the ... - MS, a devastating disease causing progressive disability, affects 2.5 ... including many young adults - FTY720 regulatory filings planned before ...
... basis of methotrexate,resistance and differences in methotrexate response, ... analysis,of the genetic determinants of resistance to the ... could offer a,pathway to predicting such resistance and ... Children,s Research Hospital study., Besides its use ...
Cached Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 2St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 3St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 4
(Date:11/26/2014)... Raleigh, NC (PRWEB) November 26, 2014 ... types of materials science can cause mesothelioma that looks ... just posted a new article on the research. ... at the Fraunhofer Institute for Toxicology and Experimental Medicine ... nanotubes. While all of the rats eventually ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 For its ... independently published The AIS Report on Blue Cross and ... WellPoint, Inc. on the varied strategies the two Blues ... improve compliance with treatments for sleep apnea, ranging from ... disorder, because it’s linked to increased rates of a ...
(Date:11/26/2014)... CA (PRWEB) November 26, 2014 With ... thousands of dollars, the prosthodontists at the Anacapa Dental Art ... for dental procedures can be daunting for some. , That ... for the procedures they offer. , “No dentist wants cost ... beautiful set of teeth,” said Dr. Mamaly Reshad, partner in ...
(Date:11/26/2014)... Sonru, the video interviewing specialist, has ... Officer and Chief Marketing Officer, in addition to the ... Jeff Jones has been appointed as Chief Operating Officer. ... role of Chief Marketing Officer. , Mr Jones is ... career includes senior roles with The Walt Disney Company ...
(Date:11/26/2014)... 2014 Call 866-997-4948 (Us-Canada Toll Free) ... the details on sales(at)researchmoz(dot)us , Researchmoz.us announces a ... market 2014" with deep study of the report on ... high blood sugar. The global glucose monitoring market has ... growing number of diabetics in the world. Their numbers ...
Breaking Medicine News(10 mins):Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 2Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 3Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 4Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 5Health News:Sonru Expansion continues with appointment of new executive team and opening of new London base 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3
... LOUIS, Dec. 10 A major new study published in ... women with breast cancer would be well-served by including soyfoods ... a decreased risk of death and cancer recurrence among the ... about 11 grams of soy protein (about two servings) per ...
... ... Hospital, announces that, after a national search, the Board of Trustees of Abington Health voted ... ... John H. Durham, chairman, Board of Trustees of Abington Health and Abington Memorial Hospital, announces ...
... , WASHINGTON, Dec. 10 The Community Oncology ... the U.S. may face closing their practices if critical Medicare ... a part of health care reform. , "Current health reform ... reimbursement and substantial cuts coming in January to cancer care," ...
... discovered a signaling pathway that tuberculosis bacteria use to ... their behalf. Epithelial cells line the airways and other ... co-opt these epithelial cells into helping create tubercles: the ... the bacteria to expand their numbers and spread to ...
... Scientists at the University of Pennsylvania School of Medicine have ... knowledge that a common cancer-related molecule called Src kinase is ... work demonstrated that Src kinases are activated in human squamous ... increasing the expression of the gene Fyn, a member of ...
... , SILVER SPRING, Md., Dec. 10 The ... solution approved to replace a portion of plasma used when ... the donor plasma to be used for other purposes. , ... States, platelets, which are blood components that help with blood ...
Cached Medicine News:Health News:Major New Study Finds Soyfoods Safe and Beneficial for Women With Breast Cancer 2Health News:Abington Health Announces New President and CEO 2Health News:Abington Health Announces New President and CEO 3Health News:National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short in Addressing Cancer Care Crisis 2Health News:National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short in Addressing Cancer Care Crisis 3Health News:National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short in Addressing Cancer Care Crisis 4Health News:Mechanism discovered by which body's cells encourage tuberculosis infection 2Health News:Mechanism discovered by which body's cells encourage tuberculosis infection 3Health News:New model of skin cancer provides insights on second-most common type of cancer 2Health News:FDA Approves First Additive Solution for Platelet Storage Up to 5 Days 2
Curved shafts with serrated 1.5 mm upper and 2 mm lower jaws. Serrated cross action handle with slide lock and polished finish. Most popular size or model....
Insertion forcep used for the Hydroview lens. Manufactured in titanium....
Folding forceps used for L161U. Manufactured in titanium....
Curved shafts with 70 degree angled 3 mm tips. Flat, cross action handle with dull finish. Most popular size or model....
Medicine Products: